29 August 2012
Aspirin could help men with prostate cancer to live longer, according to a new study.
Research published in the Journal of Clinical Oncology discovered that men who have been treated for prostate cancer, either with radiation or surgery, could significantly benefit from taking aspirin regularly.
It was found that taking the drug was linked to a lower risk of death from prostate cancer, especially in men with a high risk form of the disease.
Ten-year mortality from prostate cancer in men taking anticoagulants was found to be three per cent, compared to eight per cent in those who did not take them.
The risks of cancer recurrence and bone metastasis were also found to be significantly lower.
While anticoagulants including warfarin, clopidogrel and enoxaparin were also used in the study, it was found that the heightened survival rates were mainly due to the aspirin.
First author Dr Kevin Choe said: "The results from this study suggest that aspirin prevents the growth of tumour cells in prostate cancer, especially in high-risk prostate cancer, for which we do not have a very good treatment currently.
"But we need to better understand the optimal use of aspirin before routinely recommending it to all prostate cancer patients."
Posted by Edward Bartel
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.